Frailty and clinical outcomes in critically ill patients with cancer: A cohort study.


Journal

Journal of geriatric oncology
ISSN: 1879-4076
Titre abrégé: J Geriatr Oncol
Pays: Netherlands
ID NLM: 101534770

Informations de publication

Date de publication:
11 2022
Historique:
received: 16 08 2021
revised: 01 08 2022
accepted: 10 08 2022
pubmed: 29 8 2022
medline: 24 11 2022
entrez: 28 8 2022
Statut: ppublish

Résumé

Our aim was to assess impact of frailty on short-term clinical outcomes in critically ill patients with cancer. We conducted a cohort study at a medical and surgical intensive care unit (ICU) in Argentina. We included 269 consecutive patients, ≥18 years old, with diagnosis of cancer. We recorded demographic and clinical characteristics, Clinical Frailty Scale (CFS, ≥5 defined a patient as frail), and the number and duration of organ support therapies during ICU stay. Primary outcome was ICU and hospital mortality. Median age 69 (range 20-90); 152 (56%) patients were male. Sixty-eight (25.2%) patients presented frailty at admission. Older adults (≥65 years old) made up 62.8% of patients. Frail patients were 69.7 years versus 64.4 years for non-frail, P = 0.007, with higher Acute Physiology and Chronic Health Evaluation II (APACHE II) 14.7 ± 7 versus 10.8 ± 6, P = 0.001 and Simplified Acute Physiology Score (SAPS II) 40.1 ± 17 versus 28.7 ± 14, P = 0.001, respectively. After adjusting by age, severity score, type of admission, and type of cancer, frailty was independently associated with hospital mortality, odds ratio (OR) 4.87 (95% confidence interval [CI], 2.19-11.19, P ≤0.001). Median ICU length of stay was five days (interquartile range [IQR] 3-7) versus six days (IQR 3.8-9), in non-frail versus frail patients, respectively (P = 0.100), and hospital stay was nine days (IQR 6-17) versus 11.5 days (IQR 7-19.5) in non-frail versus frail patients, respectively (P = 0.085). Frailty as a medical condition was strongly associated with worse clinical outcomes among oncologic critically ill patients.

Identifiants

pubmed: 36031524
pii: S1879-4068(22)00197-7
doi: 10.1016/j.jgo.2022.08.006
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1156-1161

Informations de copyright

Copyright © 2022 Elsevier Ltd. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Competing Interest The authors declare they do not have any conflict of interest in relation to this study.

Auteurs

Javier Osatnik (J)

Intensive Care Unit, Hospital Alemán, Buenos Aires, Argentina. Electronic address: josatnik@hospitalaleman.com.

Agustín Matarrese (A)

Intensive Care Unit, Hospital Alemán, Buenos Aires, Argentina.

Bruno Leone (B)

Intensive Care Unit, Hospital Alemán, Buenos Aires, Argentina.

Germán Cesar (G)

Intensive Care Unit, Hospital Alemán, Buenos Aires, Argentina.

Mercedes Kleinert (M)

Intensive Care Unit, Hospital Alemán, Buenos Aires, Argentina.

Fernando Sosa (F)

Intensive Care Unit, Hospital Alemán, Buenos Aires, Argentina.

Javier Roberti (J)

CONICET, Buenos Aires, Argentina.

Daniel Ivulich (D)

Intensive Care Unit, Hospital Alemán, Buenos Aires, Argentina.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH